Research is an important step in combating the health burden caused by sexually transmitted infections (STIs). In 2018, the Centers for Disease Control and prevention (CDC) report 1 in 5 people in the US have an STI, with a total of nearly 68 million cases¹. 2021 surveillance data highlights the ongoing threat of STIs to the US, noting over 700,000 cases of gonorrhea, which is a 28% increase in the past 4 years². Antibiotic resistance (AMR) in these organisms is having a huge impact on health economy. AMR is considered a global threat, with guidelines across US, EU, UK and AU now supporting the use of AMR assays to detect antibiotic resistant STIs.

At SpeeDx, innovative technology is our backbone. The PlexZyme^® and universal probes are integral components of our patented qPCR techniques, providing clean, specific amplification with vast multiplexing capabilities.

Leaders in STI innovation, SpeeDx work closely with Key Opinion Leaders (KOLs) around the globe to address specific STI concerns. We apply our proprietary technology to help researchers further understand and combat the ongoing issue of Antimicrobial Resistance (AMR) within STI organisms. Pioneers in STI innovation, we commercialised our first product in 2016, which simultaneously detects Mycoplasma genitalium (MG) and multiple antibiotic resistance markers.

SpeeDx continue to develop STI assays addressing concerns with AMR and other unmet needs. SpeeDx innovative technology is versatile, with further research use only assays available across a number of disciplines.

SpeeDx understands the right workflow will make your work flow right.

Streamlined to minimize hands-on time

• Utilise 96-well plates for your research to maximise sample throughput and efficiency
• Streamline your research workflow and increase productivity for rapid identification. Option to include PlexPrep automation to reduce manual processes like sample handling, extraction set-up and qPCR set-up. Automation reduces human error, and the potential for reporting incorrect results. Limiting human intervention enables reallocation of staff for other tasks. [learn more about PlexPrep automation]

Flexible for easy adjustment to sample throughput, whilst maintaining productivity

• Most SpeeDx assays share universal cycling conditions. When sample numbers are lower, save time by running multiple research assays on a single 96-well plate instead of several runs.
• SpeeDx research assays are compatible with a variety of open platforms. Utilize your existing open platforms and negate the need to acquire new systems and associated service contracts.

Scalable to grow with your needs

• Simply expand your workflow solution with sample throughput. With limited instruments, process up to 1,728 samples in 24 hours, or add more systems and process up to 5,760 samples in the same time frame.
• For high throughput assays, SpeeDx creates kits for automation by including the required dead volume for the PlexPrep^®.

SpeeDx helps keep your research costs down

• Universal probes, a key component in SpeeDx multiplexing technology, enable vast multiplexing at a fraction of the cost of standard qPCR methods. We pass this benefit on to you, keeping assays affordable. [learn about our technology

• SpeeDx research assays are compatible with a variety of open platforms. You can utilize existing instrumentation that may be underutilized in the laboratory, and avoid the cost of acquiring new systems and the associated service contracts.
• SpeeDx multiplexing capabilities enable simultaneous detection of multiple targets, maximizing your output from each reaction.
• Easy to use, SpeeDx assays require minimal hands-on time, improving productivity and efficiency in the laboratory.

References

1 https://www.cdc.gov/std/statistics/prevalence-incidence-cost-2020.htm

2 https://www.cdc.gov/std/statistics/infographic.htm